OncoMatch/Clinical Trials/NCT04808323
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
Is NCT04808323 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for rectal adenocarcinoma.
Treatment: Capecitabine · Initial Dose of Radiation before Dose Escalation · Cohort A: Dose Escalation Radiation · Cohort B: Dose Escalation Radiation · Cohort C: Dose Escalation Radiation · FOLFOX — This study is a prospective, open-label, phase I design.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage I, II, III
Excluded: Stage IV
Determined on staging evaluation to be clinical stage I, II or III.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
ANC ≥ 1,000 cells/mm3; platelets ≥50,000 cells/mm3; hemoglobin ≥ 8.0 g/dl (transfusion/intervention allowed).
Kidney function
Not on hemodialysis. If age over 60, history of hypertension, diabetes or liver transplant, and GFR at enrollment is < 30 [excluded].
Liver function
ALT or AST < 4 x upper limit of normal; total bilirubin < 2 x upper normal mg/dL; alkaline phosphatase < 4 x upper limit of normal.
Laboratory values (CBC, Chem24) 45 days prior to treatment as follows: Carcinoembryonic antigen (CEA) (any value). Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3. Platelets ≥50,000 cells/mm3. Hemoglobin ≥ 8.0 g/dl. (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 4 x upper limit of normal. Total bilirubin < 2 x upper normal mg/dL. Alkaline phosphatase < 4 x upper limit of normal. Not on hemodialysis.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Froedtert & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify